Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 ROA % is 26.60% as of Jun. 2026, which is 193% above its 10-year median of 9.09. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Korea United Pharm ranks better than 90.95% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Korea United Pharm's annualizedNet Income for the quarter that ended in Jun. 2026 was ₩150,824 Mil.
Korea United Pharm's average Total Assets over the quarter that ended in Jun. 2026 was ₩566,944 Mil. Therefore, Korea United Pharm's annualized ROA % for the quarter that ended in Jun. 2026 was 26.60%.
The historical rank and industry rank for Korea United Pharm's ROA % or its related term are showing as below:
XKRX:033270'
s ROA % Range Over the Past 10 Years
Min: 6.88 Med: 9.09 Max: 14.55
Current: 14.55
During the past 13 years, Korea United Pharm's highest ROA % was 14.55%. The lowest was 6.88%. And the median was 9.09%.
XKRX:033270's ROA % is ranked better than 90.95% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.705
vs XKRX:033270: 14.55
Korea United Pharm (XKRX:033270) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Korea United Pharm ROA % Related Terms
Korea United Pharm ROA % Historical Data
* Premium members only.
The historical data trend for Korea United Pharm's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's ROA % distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Korea United Pharm (XKRX:033270) has a ROA % of 26.60% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Korea United Pharm and its competitors. This is 193% above median its historical median of 9.09. Over the past decade, Korea United Pharm's ROA % has ranged from 6.88 to 14.55. According to the industry distribution chart, Korea United Pharm ranks #91 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 9%.
Is Korea United Pharm's ROA % too high?
Korea United Pharm's current ROA % of 26.60% is 193% above median its 10-year median of 9.09. Over the past 10 years, this metric has ranged from a low of 6.88 to a high of 14.55. The Drug Manufacturers industry median ROA % is 2.71. Korea United Pharm's value of 26.60% is 883.4% above this industry median. Based on the distribution chart, Korea United Pharm ranks #91 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #91 out of 1006 companies for ROA %. This places Korea United Pharm in the top 9% of its industry — outperforming the majority of peers. The industry median ROA % is 2.71. Korea United Pharm's value of 26.60% is 883.4% above this benchmark. Historically, Korea United Pharm's own ROA % has ranged from 6.88 to 14.55 over the past decade. While the company's 10-year median is 9.09 vs. the industry median of 2.71, Korea United Pharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.71, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current ROA % of 26.60% is 883.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current ROA % is 26.60%, which is 193% above median its own 10-year median of 9.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current ROA % is 26.60%, which is 193% above median its 10-year median of 9.09 and 883.4% above the Drug Manufacturers industry median of 2.71. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current ROA % is 26.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
ROA %: 26.60% (193% above median its 10-year median of 9.09)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 883.4% above the Drug Manufacturers median (#91 of 1006)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
